PanamaTimes

Saturday, Jul 05, 2025

0:00
0:00

Pfizer, the EU, and disappearing ink - Smoke, Mirrors, and the Billion-Dose Pfizer Vaccine Deal: EU's 'Open Secret

It's as if Pfizer's massive COVID-19 vaccine deal with the European Commission were written with disappearing ink: the more time passes, the more details seem to vanish and makes it harder to trace how much bribe the people who signed the deal got from Pfizer for forcing citizens to consume their ineffective and sometimes harmful products.
One can only marvel at the artful vanishing act surrounding Pfizer's colossal COVID-19 vaccine contract with the European Commission. It's as though penned with vanishing ink; with every tick of the clock, crucial details mysteriously evaporate.

The center stage of this ongoing charade is the cloak-and-dagger text communication between Commission President Ursula von der Leyen and Pfizer's CEO Albert Bourla leading up to the 1.1 billion dose deal in April 2021. The Commission dismisses any calls for transparency on these messages with a fat "no comment," practically a slap to the face of public trust.

Recently, the Commission declared a newly minted deal with Pfizer, altering the contract terms. The initial 450 million doses due in 2023 are now stretched over four years. What's the new quantity of obligatory doses? What are the revised financial terms? If you're looking for answers, good luck – the Commission remains maddeningly tight-lipped.

The Commission's refusal to shine light on this deal reeks of a disturbing lack of transparency. A Brussels journalist's request to view the elusive text exchanges between von der Leyen and Bourla was flatly denied, an act drawing sharp criticism from the European Ombudsman. It seems that any attempt to probe into this high-stakes deal, whether by the EU's budget watchdog or the European Parliament's COVID-19 committee, has been stonewalled.

Rewind to April 2021. The Commission was all too happy to flaunt its colossal deal of up to 1.8 billion doses from the U.S.-Germany pharma alliance of Pfizer and BioNTech. In a desperate scramble for vaccine supply amid the pandemic, this deal provided enough doses to inoculate the EU's adult population thrice over. But the victory fanfare has long since died down, replaced with the clamor of unanswered questions and billions of wasted euros.

Now, with COVID-19 on its last legs and vaccination rates hitting a wall, the colossal deal has become a colossal headache. EU countries are shackled to a contract compelling them to purchase exorbitant quantities of vaccine doses. Add to this, a shocking volume of doses have already been trashed due to short shelf life. An astounding 36.6 million doses in Germany and 17.5 million doses in Austria were left unused, deemed 'available for vaccination.'

This deal's complete absence of a backout clause based on pandemic conditions reeks of incompetence, particularly given the wavering waves of the coronavirus apparent by April 2021. Sure, EU officials paint it as a necessary safety net, but is it justifiable to hemorrhage billions on potentially wasted doses?

A coalition of Eastern and Central European countries, already buckling under the financial strain of Russia's invasion of Ukraine and a refugee influx, sees it differently. They're vociferously demanding contract renegotiations, perhaps a beacon of sanity in this bureaucratic circus.

Despite concerted efforts by journalists, politicians, and watchdogs to unravel the peculiar negotiation process, the veil of secrecy remains firmly in place. Even the New York Times, where von der Leyen had once basked in her victory, is now suing the Commission for the release of these enigmatic text messages.

The Commission, despite the swirling storm of controversy, still insists on the success of the contract. Yet, the subtle announcement, tucked away in an emailed news roundup on a Friday lunchtime ahead of a long weekend, certainly doesn't scream 'triumph.' Dodging queries about the decision not to reveal the revised total number of doses, a

detail disclosed in the original contract, the Commission shamelessly sidestepped responsibility onto national governments.

Von der Leyen is probably banking on this latest deal to bring the curtain down on this controversy. Yet, the European Public Prosecutor's Office's announcement last October about a probe into the EU's vaccine procurement may throw a wrench into her aspirations for a second term. If the Commission President lands in their crosshairs, her political future might go from a seemingly guaranteed encore to a swift exit from the stage.
Newsletter

Related Articles

PanamaTimes
0:00
0:00
Close
AI Raises Alarms Over Long-Term Job Security
House Oversight Committee Subpoenas Former Jill Biden Aide Amid Investigation into Alleged Concealment of President Biden's Cognitive Health
OpenAI Secures Multimillion-Dollar AI Contracts with Pentagon, India, and Grab
Brazilian Congress Rejects Lula's Proposed Tax Increase on Financial Transactions
Landslide in Bello, Colombia, Results in Multiple Casualties
Papa Johns pizza surge near the Pentagon tipped off social media before Trump's decisive Iran strike
Juncker Criticizes EU Inaction on Trump Tariffs
Minnesota Lawmaker Melissa Hortman and Husband Killed in Targeted Attack; Senator John Hoffman and Wife Injured
Wreck of $17 Billion San José Galleon Identified Off Colombia After 300 Years
Sole Survivor of Air India Crash Recounts Escape
Coinbase CEO Warns Bitcoin Could Supplant US Dollar Amid Mounting National Debt
UK and EU Reach Agreement on Gibraltar's Schengen Integration
Israeli Finance Minister Imposes Banking Penalties on Palestinians
U.S. Inflation Rises to 2.4% in May Amid Trade Tensions
Trump's Policies Prompt Decline in Chinese Student Enrollment in U.S.
Global Oceans Near Record Temperatures as CO₂ Levels Climb
Trump Announces U.S.-China Trade Deal Covering Rare Earths
Smuggled U.S. Fuel Funds Mexican Cartels Amid Crackdown
Protests Erupt in Los Angeles with Symbolic Flag Burning
Trump Administration Issues New Travel Ban Targeting 12 Countries
Man Group Mandates Full-Time Office Return for Quantitative Analysts
JPMorgan Warns Analysts Against Accepting Future-Dated Job Offers
Builder.ai Faces Legal Scrutiny Amid Financial Misreporting Allegations
Japan Grapples with Rice Shortage Amid Soaring Prices
Goldman Sachs Reduces Risk Exposure Amid Market Volatility
HSBC Chairman Mark Tucker to Return to AIA as Non-Executive Chair
Israel Confirms Arming Gaza Clan to Counter Hamas Influence
Judge Blocks Trump's Ban on International Students at Harvard
Trump Proposes Travel Ban on 'Uncontrolled' Countries
Panama Port Owner Balances US-China Pressures
Trump Administration Accused of Obstructing Deportation Cases
Trump’s China Strategy Remains a Geopolitical Puzzle
Eurozone Inflation Falls Below ECB Target to 1.9%
Call for a New Chapter in Globalisation Emerges
Blackstone and Rivals Diverge on Private Equity Strategy
Mayor’s Security Officer Implicated | Shocking New Details Emerge in NYC Kidnapping Case
Bangkok Ranked World's Top City for Remote Work in 2025
Denmark Increases Retirement Age to 70, Setting a European Precedent
Netanyahu Accuses Western Leaders of 'Emboldening Hamas'
Escalating Trade Tensions and Market Reactions
OnlyFans Reportedly in Talks for $8 Billion Sale
JBS Gains Shareholder Approval for U.S. Stock Listing
Booz Allen Hamilton to Cut 2,500 Jobs Amid Federal Spending Reductions
Trump Signs Executive Orders to Accelerate Nuclear Energy Development
Harvard Temporarily Blocks Trump Administration's International Student Ban
Nippon Steel Forms Partnership with U.S. Steel, Headquarters to Remain in Pittsburgh
Trump Expands Tariff Threats to Apple and Samsung Devices
Oracle and OpenAI Plan $40 Billion Nvidia Chip Purchase for AI Data Center
Trump Threatens 50% Tariff on EU Goods, Markets React
The Daily Debate: The Fall of the Dollar — Strategic Reset or Economic Self-Destruction?
×